2025 Clinician Corner - Respiratory failure in a patient with exhaled nitric oxide >300 ppb and subsequent response to dupilmab

2025 Clinician Corner - Respiratory failure in a patient with exhaled nitric oxide >300 ppb and subsequent response to dupilmab

Multiple biologic agents are approved for the treatment of severe persistent asthma not controlled by inhaled corticosteroid/beta-agonist therapy. Appropriate phenotyping can aid in picking the right biologic for the right patient. Here is a unique case of a patient with severe asthma and respiratory arrest, with fraction of exhaled nitric oxide >300 ppb whose asthma became completely controlled with dupilumab.

  • Provider:A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health
  • Activity Link: https://ce.bswhealth.com/node/34536
  • Start Date: 2025-01-01 06:00:00
  • End Date: 2025-01-01 06:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
  • MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
    ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
  • Commercial Support: No
  • Activity Type: Journal-based CE
  • CME Finder Type: Other
  • Fee to Participate: Yes
  • Measured Outcome: Learner Competence, Learner Knowledge
  • Provider Ship: Directly Provided
  • Registration: Open to all
  • Specialty: General Surgery, Internal Medicine
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.